Focus:
News
-
25 March 2019
ICR scientists find triple combination stops drug resistance in bowel cancer
Scientists from the Institute of Cancer Research (ICR), London, have discovered how bowel cancer cells become resistant to targeted drugs, as well as finding that a triple combination therapy can...
-
25 March 2019
Janssen seeks approval for new applications of multiple myeloma drug
Janssen Pharmaceutica has filed an application with the European Medicines Agency for expanded indication of Darzalex to treat multiple myeloma.
-
25 March 2019
Thermo Fisher to buy Brammer Bio for $1.7bn
Thermo Fisher Scientific has signed a definitive agreement to acquire viral vector manufacturing company Brammer Bio for a cash consideration of around $1.7bn.
-
25 March 2019
Study finds new drug combo could treat paediatric brain tumour
A new study conducted by the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine has showed that carboplatin and everolimus combination could help treat paediatric...
-
22 March 2019
Genomics England signs immunotherapy partnership with CCG
NHS England spin-out Genomics England and artificial intelligence (AI)-focused Cambridge Cancer Genomics (CCG.ai) have announced they have entered into an immunology partnership.
-
22 March 2019
Biogen and Eisai terminate trial of Alzheimer’s drug on efficacy grounds
Biogen and Eisai have announced they are discontinuing two Phase III trials, Engage and Emerge, evaluating the safety and efficacy of aducanumab in patients with Alzheimer’s disease and mild Alzheimer’s...
-
22 March 2019
UK MHRA recalls more batches of sartan medication
The UK Medicines and Healthcare Products Regulatory Agency has recalled three more batches of Losartan tablets amid fears of contamination with NMBA.
-
22 March 2019
FDA approves Jazz Pharma’s sleep disorder drug Sunosi
The US Food and Drug Administration has approved Ireland-based Jazz Pharmaceuticals’ Sunosi drug to treat adults suffering from excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea
-
22 March 2019
Takeda and HemoShear to develop new liver disease drugs
Takeda Pharmaceutical has expanded its exclusive drug discovery alliance with biotechnology firm HemoShear Therapeutics to discover and develop additional new therapies for liver diseases.
-
21 March 2019
Celgene signs $25m AI drug discovery partnership with Exscientia
Oxford-based artificial intelligence (AI) drug discovery company Exscientia has announced it has entered into three-year partnership with Celgene for an initial upfront payment of $25m.